Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin

Our study evaluates the efficacy of IGIV treatment in PPS on clinical (walking and pain) and isokinetic (muscle strength) criteria, on patients with PS at Montpellier's Hospital

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Post-Poliomyélitis Syndrom Central Nervous System Diseases Central Nervous System Infections Enterovirus Infections Infections Muscular Diseases Muscular Disorders, Atrophic Musculoskeletal Diseases Myelitis Nervous System Diseases Neurodegenerative Diseases Neuroinflammatory Diseases Neuromuscular Diseases Picornaviridae Infections Poliomyelitis Postpoliomyelitis Syndrome RNA Virus Infections Spinal Cord Diseases Virus Diseases

Age range

30 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Uh Montpellier

Montpellier, 34295, France

About this study

Patients are admitted to a multidisciplinary consultation (neurologist, PMK) to validate the indication of treatment with IGIV. Realization of a pre-therapeutic evaluation in the department of MPR on the criteria of judgment, then the patient is admitted in a service of neurology to benefit from the cure of IGIV. The patient is then re-admitted to a PMR service for post-treatment evaluation.

Collection of data retrospectively.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of PPS
Pre- and post-therapeutic evaluation carried out
Data transcribed in the computerized patient file

Exclusion criteria

No walking patient

Treatment and study plan

Primary outcomes

Muscular strength

Time frame: 5 months

Muscular strength with isokinetic

Secondary outcomes

Walking perimeter

Time frame: 5 months

Walking perimeter with walking test (6 minutes)

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin: a Retrospective Study of Efficacy on Clinical and Isokinetic Criteria

Acronym: PPS and IGIV

Important dates

Study start: 2019
Primary completion: 2019
Study completion: 2019
First posted: Jul 2, 2019
Registry last updated: Mar 10, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed